[Prospective controlled study of therapy of chronic myeloid leukemia (CML)].
The current status of the prospective German multicenter study on the therapy of chronic myelogenous leukemia (CML) is reported. After three years 188 of the projected 300 patients have been randomized. The duration of the study will be 8 years. The clinical characteristics of the randomized patients correspond well to those reported in the literature. Risk factors are distributed equally in both arms. One problem is the relatively high drop-out rate of about 12% thus far. Survival curves for the two treatment arms will be presented, although at present the number of patients having reached the end of the chronic phase is too small to allow definitive evaluation.
Hehlmann
R
R
Heimpel
H
H
Hossfeld
D K
DK
Köpcke
W
W
Kolb
H J
HJ
Löffler
H
H
Pralle
H
H
Queisser
W
W
Anger
B
B
Bergmann
L
L
D000328:Adult; D000368:Aged; D002066:Busulfan / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D007370:Interferon Type I / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008875:Middle Aged; D010677:Philadelphia Chromosome; D011897:Random Allocation; D011994:Recombinant Proteins / Q000627:therapeutic use
D007370:Interferon Type I; D011994:Recombinant Proteins; D002066:Busulfan; D006918:Hydroxyurea
Prospektive kontrollierte Studie zur Therapie der chronisch myeloischen Leukämie (CML).